Skip to main
TVTX

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics is poised for success due to its strong pipeline of investigational products, including its lead candidate sparsentan, which has shown promising results in treating rare kidney disorders like FSGS and IgAN. With its recent FDA approval and a potential expansion of exclusivity, the company's sales and earnings are expected to continue growing in the coming years. Furthermore, the recent convertible debt offering provides the company with financial flexibility to support its operations. Overall, Travere's unique market position and strong financials make it an attractive investment opportunity.

Bears say

Travere Therapeutics is facing upcoming competition from other companies in the rare kidney disease market, as well as potential setbacks in its commercial execution that could impact its stock negatively. The company's promising pipeline drug, Filspari, has shown demand in the IgA nephropathy (IgAN) market, but there is uncertainty about its potential success in the FSGS market as there are currently no identified major groups that would not use the drug. Additionally, the recent licensing deal for an early-stage asset may provide potential upside, but it also adds uncertainty to the company's plans and development timelines.

Travere Therapeutics (TVTX) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 11 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $62.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $62.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.